Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 6, 2010, Pages 2616-2621

  Mukasa, Akitake ^a,d   Wykosky, Jill ^a   Ligon, Keith L ^b,c   Chin, Lynda ^b   Cavenee, Webster K ^a   Furnari, Frank ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Epidermal growth factor receptor; Gliomblastoma; Tumorigenicity

Indexed keywords

DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CARCINOGENICITY; GENE SILENCING; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DOXYCYCLINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; MICE; MICE, NUDE; MUTATION; NEOPLASMS, EXPERIMENTAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 77249101567     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914356107     Document Type: Article

References (36)

1. Louis DN, et al., eds (2007) The 2007 WHO Classification of Tumours of the Central Nervous System (IARC, Lyon, France), Vol 114, pp 97-109.
2. Libermann TA, et al. (1985) Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 313:144-147.
3. Ekstrand AJ, et al. (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172.
4. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 87:8602-8606.
5. Nishikawa R, et al. (1994) A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA 91:7727-7731.
6. Nagane M, et al. (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079-5086.
7. Narita Y, et al. (2002) Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res 62:6764-6769.
8. Heimberger AB, et al. (2005) Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 11:1462-1466.
9. Shinojima N, et al. (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962-6970.
10. Loew S, Schmidt U, Unterberg A, Halatsch ME (2009) The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. Anticancer Agents Med Chem 9:703-715.
11. Holmen SL, Williams BO (2005) Essential role for Ras signaling in glioblastoma maintenance. Cancer Res 65:8250-8255.
12. Chin L, et al. (1999) Essential role for oncogenic Ras in tumour maintenance. Nature 400:468-472.
13. Ji H, et al. (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103:7817-7822.
14. Roberts RB, et al. (2002) Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 99:1521-1526.
15. Mellinghoff IK, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024.
16. Lassman AB, et al. (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: Tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin Cancer Res 11:7841-7850.
17. Rich JN, et al. (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142.
18. Camp ER, et al. (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11:397-405.
19. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207.
20. Huang PH, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867-12872.
21. Stommel JM, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290.
22. Brennan C, et al. (2004) High-resolution global profiling of genomic alterations with long oligonucleotide microarray. Cancer Res 64:4744-4748.
23. Rhodes DR, et al. (2004) ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 6:1-6.
24. Lal A, Sui IM, Riggins GJ (1999) Serial analysis of gene expression: Probing transcriptomes for molecular targets. Curr Opin Mol Ther 1:720-726.
25. Li B, Chang CM, Yuan M, McKenna WG, Shu HK (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63:7443-7450.
26. Adams J, Kelso R, Cooley L (2000) The kelch repeat superfamily of proteins: Propellers of cell function. Trends Cell Biol 10:17-24.
27. Neuhaus P, et al. (2006) Overexpression of Kelch domain containing-2 (mKlhdc2) inhibits differentiation and directed migration of C2C12 myoblasts. Exp Cell Res 312:3049-3059.
28. Riemenschneider MJ, et al. (1999) Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 59:6091-6096.
29. Liang Y, et al. (2005) Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 102:5814-5819.
30. Sun L, et al. (2006) Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9:287-300.
31. Freije WA, et al. (2004) Gene expression profiling of gliomas strongly predicts survival. Cancer Res 64:6503-6510.
32. Phillips HS, et al. (2006) Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9:157-173.
33. Finak G, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14:518-527.
34. Giannini C, et al. (2005) Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol 7:164-176.
35. Humphrey PA, et al. (1988) Amplification and expression of the epidermal growth factor receptor gene in human glioma xenografts. Cancer Res 48:2231-2238.
36. Goudar RK, et al. (2005) Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4:101-112.